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and Early Tumor Promotional Events in Rat Experimental Model
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Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi 110062, India
Plants have been widely used as protective agents against a wide variety of processes and compounds
that damage tissues via free radical mechanisms. Perillyl alcohol (PA) is a naturally occurring
monoterpene found in the essential oils of numerous species of plants including mints, cherries and
celery seeds. This monocyclic monoterpene has shown antioxidant and therapeutic activity in various
studies against various xenobiotics. In this study, we have analyzed the effects of PA against single
intraperitoneal dose of ferric nitrilotriacetate (Fe-NTA) (9 mg iron per kg body weight)-induced
nephrotoxicity and early tumor promotional events. The pretreatment of Fe-NTA-treated rats with 0.5%
per kg body weight dose and 1% per kg body weight dose of PA for seven consecutive days significantly
reversed the Fe-NTA-induced malondialdehyde formation, xanthine oxidase activity (P < 0.001),
ornithine decarboxylase activity (P < 0.001) and
3[H]thymidine incorporation in renal DNA (P < 0.001)
with simultaneous significant depletion in serum toxicity markers blood urea nitrogen and creatinine
(P < 0.001). Significant restoration at both the doses was recorded in depleted renal glutathione content,
and its dependent enzymes with prophylactic treatment of PA. Present results suggest that PA potentially
attenuates against Fe-NTA-induced oxidative damage and tumor promotional events that preclude its
development as a future drug to avert the free radical-induced toxicity.
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Introduction
Ferric nitrilotriacetate (Fe-NTA), an established nephrotoxi-
cant (1), induces iron-dependent lipid peroxidation (LPO),
leading to acute tubular necrosis (1,2). Nitrilotriacetic acid
(NTA) is used as polyphosphate substitute in detergents in
various countries (3); it forms water-soluble chelate complexes
with metal cations at neutral pH (4). Intraperitoneal adminis-
tration of Fe-NTA has shown to induce renal proximal tubular
necrosis and renal adenocarcinoma (5). Several phytochemi-
cals and micronutrients present in fruits and vegetables are
often considered as cancer-chemopreventive agents. Perillyl
alcohol (PA), a monoterpene is isolated from the essential oils
of lavender and several other plants (6,7). Monoterpenes are
formed in the mevalonic acid pathway in plants, some aspects
of cholesterol metabolism were thought to be involved in
cancer growth and monoterpenes have been shown to interfere
with animal cholesterol synthesis, thereby reducing cholesterol
levels and hence suppression in tumor promotion (7).
Monoterpenes increase levels of liver enzymes involved in
detoxifying xenobiotics (8). Animal studies have demonstrated
that monoterpenes inhibit the formation of chemically
induced breast, colon, liver, skin and pancreatic tumors (9).
A variety of mechanisms are proposed to explain PA’s
chemopreventive and chemotherapeutic effects. One such
mechanism is that it promotes ‘apoptosis’, a self-destructing
ability the cell has when its DNA is severely damaged. In
cancer, these cells lack this self-destructing ability, resulting in
abnormal cell growth (10–12). PA is one of the promising
bioactive food components being investigated at the National
Cancer Institute in prevention clinical trials to reduce breast
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experimental studies (14). In addition, in vitro data suggest its
efficacy in treating neuroblastomas and leukemias (14). PA
actively induces apoptosis in cancer cells without affecting
normal cells and may revert tumor cells back to a differentiated
state (15). It has been shown to induce mannose-6-phosphate/
insulin-like growth factor II receptors, decrease ras protein
prenylation, decrease ubiquinone synthesis, and induce Phase I
and Phase II detoxification systems (16). Hence, this study is
aimed to investigate the efficacy of PA in ameliorating the
toxic effects via inhibiting oxidative damage and tumor
promotion of Fe-NTA in a rat experimental model.
Methods
Chemicals
PA was purchased from ACROS Organics from NJ, USA.
[
14C]ornithine (specific activity 56 mCi mmol) and [
3H]thymi-
dine (specific activity 82 Ci mmol) were purchased from
Amersham Corporation (UK). All other chemicals were of the
highest purity and commercially available.
Experimental Design
The treatment regimen for PA was based on the preliminary
studies carried out in our laboratory. To study the biochemical
and serological changes, 25 male Wistar rats (150–200 g) were
divided into five groups with equal number of animals in each
group. The study was approved with the Committee for the
purpose of control and supervision of experimental animals
(CPCSEA). Registration number and date of registration: 173/
CPCSEA, January 28, 2000. CPCSEA guidelines were
followed for animal handling and treatment.
Group I served as saline-treated control and was adminis-
tered with saline (0.85%). Group II served as treated control
and was administered Fe-NTA (9 mg Fe per kg body weight)
only. Fe-NTA solution was prepared fresh immediately before
its use by the method of Awai et al. (17). Groups III and IV
were pretreated with PA orally at doses 0.5% per kg body
weight and 1% per kg body weight for seven consecutive days
followed by administration of Fe-NTA (9 mg Fe per kg body
weight i.p.) on the 7th day. Group V was given higher dose
(D2) of PA for seven consecutive days. All rats were sacrificed
12 h after toxicant administration. Blood was collected from
para-orbital venous complexes and serum was separated and
stored at 4 C for the estimation of blood urea nitrogen (BUN)
and creatinine. Kidney tissue was processed for estimating
renal ornithine decarboxylase (ODC) activity, reduced glu-
tathione (GSH) content, microsomal LPO and other biochemi-
cal estimations.
For [
3H]thymidine incorporation 25 male Wistar rats were
divided into five groups,same treatment regimen was followed
except all were given intraperitoneal [
3H]thymidine (30 mCi
per 0.2 ml saline per animal) 2 h before sacrifice. Time of
sacrifice was after 18 h of Fe-NTA (9 mg Fe per kg body
weight i.p.) administration; kidney sections were quickly
excised, rinsed with ice-cold saline, freed of extraneous
material and processed for the quantification of [
3H]thymidine
incorporation into the renal DNA. Time of sacrifice for the
DNA synthesis study was decided as per the preliminary
studies carried in our laboratory (1).
Post-Mitochondrial Supernatant and
Microsome Preparation
Tissue processing and preparation of post-mitochondrial
supernatant (PMS) were done as described by Athar and Iqbal
(18). Kidneys were removed quickly, cleaned free of extrane-
ous material and immediately perfused with ice-cold saline
(0.85% sodium chloride). The kidneys were homogenized in
chilled phosphate buffer (0.1 M, pH 7.4) containing KCI
(1.17%) using a Potter Elvehjen homogenizer. The
homogenate was filtered through muslin cloth, and was
centrifuged at 800· g for 5 min at 4 C by Eltek Refrigerated
Centrifuge (model RC 4100 D) to separate the nuclear debris.
The aliquot so obtained was centrifuged at 12 000 r.p.m. for
20 min at 4 C to obtain PMS, which was used as a source of
enzymes. A portion of the PMS was centrifuged for 60 min by
ultracentrifuge (Beckman L7-55) at 34 000 r.p.m. at 4 C. The
pellet was washed with phosphate buffer (0.1 M, pH 7.4)
containing KCI (1.17%). All the biochemical estimations were
completed within 24 h of animal sacrifice.
Biochemical Estimations
Reduced GSH estimated by the yellow color on a
spectrophotometer
Reduced GSH was determined by the method of Jollow et al.
(19). One milliliter sample of PMS was precipitated with
1.0 ml of sulfosalicylic acid (4%). The samples were kept at
4 C for 1 h and then centrifuged at 1200· g for 20 min at 4 C.
The assay mixture contained 0.1 ml filtered aliquot, 2.7 ml
phosphate buffer (0.1 M, pH 7.4) and 0.2 ml 1,2-dithio-
bisnitrobenzoic acid (DTNB) (100 mM) in a total volume of
3.0 ml. The yellow color developed was read at 412 nm on a
spectrophotometer.
Glutathione peroxidase activity was assayed by the method
of Mohandas et al. (20). The reaction mixture consisted of
1.49 ml phosphate buffer (0.1 M, pH 7.4), 0.1 ml EDTA
(1 mM), 0.1 ml sodium azide (1 mM), 0.05 ml glutathione
reductase (GR) (1 IU ml
 1), 0.05 ml GSH (1 mM), 0.1 ml
NADPH (0.2 mM), 0.01 ml H2O2 (0.25 mM) and 0.1 ml 10%
PMS in a total volume of 2 ml. The disappearance of NADPH
at 340 nm was recorded at 25 C. Enzyme activity was
calculated as nmol NADPH oxidized per min per mg protein




440 Activity of perillyl alcoholEnzyme activity quantitated at 25 C by measuring
disappearance of NADPH
GR activity was determined by the method of Carlberg and
Mannervik (21). The reaction mixture consisted of 1.65 ml
phosphate buffer (0.1 M, pH 7.6), 0.1 ml EDTA (0.5 mM),
0.05 ml oxidized GSH (1 mM), 0.1 ml nicotinamide adenine
dinucleotide phosphate reduced (NADPH) (0.1 mM) and
0.1 ml 10% PMS in a total volume of 2 ml. Enzyme activity
was quantitated at 25 C by measuring disappearance of
NADPH at 340 nm and was calculated as nmol NADPH
oxidized per min per mg protein using molar extinction




Glucose-6-phosphate dehydrogenase activity determined
by changes in absorbance
The activity of glucose-6-phosphate dehydrogenase was
determined by the method of Zaheer et al. (22). The reaction
mixture consisted of 0.3 ml Tris–HCl buffer (0.05 M, pH 7.6),
0.1 ml NADP (0.1 mM), 0.1 ml glucose-6-phosphate
(0.8 mM), 0.1 ml MgCl2 (8 mM), 0.3 ml PMS (10%) and
2.1 ml distilled water in a total volume of 3 ml. The changes in
absorbance were recorded at 340 nm and enzyme activity was
calculated as nmol NADP reduced per min per mg protein





The assay for microsomal LPO was done following the method
of Wright et al. (23). The reaction mixture in a total volume of
1.0 ml contained 0.58 ml phosphate buffer (0.1 M, pH 7.4),
0.2 ml microsomes, 0.2 ml ascorbic acid (100 mM) and 0.02 ml
ferricchloride(100mM).Thereactionmixturewasincubatedat
37 C in a shaking water bath for 1 h. The reaction was stopped
byadding1.0ml10% trichloroacetic acid(TCA). Followingthe
addition of 1.0 ml 0.67% thiobarbituric acid (TBA), all tubes
were placed in boiling water bath for 20 min and then shifted to
crushed ice-bath before centrifuging at 2500· g for 10 min.
The amount of malondialdehyde (MDA) formed in each of the
samples was assessed by measuring optical density of the
supernatant at 535 nm using spectrophotometer (Milton Roy
21 D) against a reagent blank. The results were expressed as
nmol MDA formed per hour per gram tissue at 37 Cu s i n g




Assay for Xanthine Oxidase Activity
The activity of xanthine oxidase (XO) was assayed by the
method of Stripe and Della Corte (24). The reaction mixture
consisted of 0.2 ml PMS that was incubated for 5 min at 37 C
with 0.8 ml phosphate buffer (0.1 M, pH 7.4). The reaction was
started by adding 0.1 ml xanthine (9 mM) and kept at 37 C for
20 min. The reaction was terminated by adding of 0.5 ml ice-
cold perchloric acid (PCA) (10% v/v). After 10 min, 2.4 ml
of distilled water was added and centrifuged at 4000 r.p.m. for
10 min and mg uric acid formed per minute per mg protein was
recorded at 290 nm.
Catalase Activity
Catalase activity was assayed by the method of Claiborne (25).
The reaction mixture consisted of 1.95 ml phosphate buffer
(0.1 M, pH 7.4), 1.0 ml hydrogen peroxide (0.019 M) and
0.05 ml 10% PMS in a final volume of 3 ml. Changes in
absorbance were recorded at 240 nm. Catalase activity was
calculated as nmol H2O2 consumed per min per mg protein.
Blood Urea Nitrogen
Estimation of BUN was done by diacetyl monoxime method of
Kanter (26). Protein-free filtrate was prepared by adding serum
and equal amount of 10% TCA, then mixture was centrifuged
at 2000 r.p.m. and supernatant was taken. To 0.5 ml of protein-
free filtrate, were added 3.5 ml of distilled water, 0.8 ml
diacetylmonoxime (2%) and 3.2 ml sulphuric acid–phosphoric
acid reagent (reagent was prepared by mixing 150 ml 85%
phosphoric acid with 140 ml water and 50 ml of concentrated
sulphuric acid). The reaction mixture was placed in a boiling
water bath for 30 min and then cooled. The absorbance was
read at 480 nm.
Creatinine
Creatinine was estimated by the alkaline picrate method of
Hare (27). Protein-free filtrate was prepared. To 1.0 ml serum
were added, 1.0 ml sodium tungstate (5%), 1.0 ml sulfuric acid
(0.6 N) and 1.0 ml distilled water. After mixing thoroughly, the
mixture was centrifuged at 800· g for 5 min. The supernatant
was added to a mixture containing 1.0 ml picric acid (1.05%)
and 1.0 ml sodium hydroxide (0.75 N). The absorbance at
520 nm was read exactly after 20 min.
Assay for ornithine decarboxylase activity
ODC activity was determined using 0.4 ml renal 105 000 g
supernatant fraction per assay tube by measuring release of
14CO2 from [
14C]ornithine by the method of O’Brien et al.
(28). The kidneys were homogenized in Tris–HCl buffer
(pH 7.5, 50 mM) containing EDTA (0.1 mM), pyridoxal
phosphate (0.1 mM), phenylmethyl sulfonylfluoride (PMSF)
(1.0mM),2-mercaptoethanol(1.0mM),dithiothreitol(0.1mM)
and Tween 80 (0.1%) at 4 C. In brief, the reaction mixture
contained 400 ml cytosol and 0.095 ml co-factor mixture
containing pyridoxal phosphate (0.32 mM), EDTA (0.4 mM),
dithiothreitol (4.0 mM), ornithine (0.4 mM), Brig 35 (0.02%)
and [
14C]ornithine (0.05 mCi) in a total volume of 0.495 ml.
After adding buffer and co-factor mixture to blank and other
test tubes, the tubes were closed immediately with a rubber
stopper containing 0.2 ml ethanolamine and methoxyethanol
mixture in the central well and kept in a water bath at 37 C.
After 1 h of incubation, the enzyme activity was arrested by
injecting 1.0 ml citric acid solution (2.0 M) along the sides of
glass tubes and the incubation was continued for 1 h to ensure
complete absorption of
14CO2. Finally, the central well was
transferred to a vial containing 2 ml ethanol and 10 ml
toluene-based scintillation fluid was added. Radioactivity was
eCAM 2007;4(4) 441counted in a liquid scintillation counter (LKB Wallace-1410).
ODC activity was expressed as pmol
14CO2 released per hour
per mg protein.
Renal DNA Synthesis
The isolation of renal DNA and assessment of incorporation of
[
3H]thymidine into DNA were carried out by the method of
Smart et al. (29). The rat kidneys were quickly removed
and cleaned free of extraneous material and homogenate
(10% w/v) was prepared in ice-cold water. The precipitate thus
obtained was washed with cold TCA (5%) and incubated with
cold PCA (10%) at 4 C overnight. After this, incubation
mixture was centrifuged and the precipitate was washed with
cold PCA (5%). The precipitate was dissolved in warm PCA
(10%), incubated in a boiling water bath for 30 min and filtered
through Whatman 50 paper. The filtrate was used for [
3H]
counting in a liquid scintillation counter (LKB Wallace-1410)
after adding scintillation fluid. The amount of DNA in the
filtrate was estimated by the diphenylamine method of Giles
and Myers (30). The amount of [
3H]thymidine incorporated
was expressed as d.p.m. per mg DNA. The protein concentra-
tion in all (both enzymatic and ODC) samples was determined
by the method of Lowry et al. (31).
Statistical Analysis
Differences between groups were analyzed using analysis
of variance (ANOVA) followed by Dunnett’s multiple
comparisons test. All data points are presented as the treatment
groups mean ± standard error of the mean (SEM).
Results
PA Pretreatment Inhibits Renal Toxicity Markers BUN
and Creatinine
The effect of prophylactic administration of PA on Fe-NTA
mediated leakage of kidneymarker enzymes in serum is shown
in Figs 1 and 2. Only Fe-NTA treatment induced BUN by
224% and creatinine by 105% as compared with saline.
Marked inhibition in BUN 42% at dose I and by 65% at
dose II, creatinine level was inhibited by 37% at dose I and
44% at higher dose in PA-treated groups.
Tumor Promotion Markers Significantly Inhibited by
PA Pretreatment
The results of treatment of PA on tumor promotion markers,
namely ODC and renal DNA synthesis are presented in Figs 3
and 4. Administration of Fe-NTA resulted in increased rate of
[
3H]thymidine incorporation by 459% into renal DNA and
increase by 165% in ODC activities, which are often
considered as early markers of tumor promotion. The
prophylactic treatment of rats with PA showed a marked
simultaneous and significant inhibition of ODC activity by
24% at low dose and 45% at higher dose. A marked
suppressing effect by dose I 30% and 55% by dose II on the
rate [
3H]thymidine incorporation into renal DNA was recorded
treated controls.
     
Figure 1. Results represent mean ± SE of five animals per group. Results
obtained are significantly different from saline-treated group (**P < 0.001).
Results obtained are significantly different from Fe-NTA-treated group
(*P < 0.001). PA, perillyl alcohol; D1 ¼ 0.5%; D2 ¼ 1%.
Figure 2. Results represent mean ± SE of five animals per group. Results
obtained are significantly different from saline-treated group (**P < 0.001).
Results obtained are significantly different from Fe-NTA-treated group
(*P < 0.001). PA, perillyl alcohol; D1 ¼ 0.5%; D2 ¼ 1%.
Figure 3. Results represent mean ± SE of five animals per group. Results
obtained are significantly different from saline-treated group (**P < 0.001).
Results obtained are significantly different from Fe-NTA-treated group
(*P < 0.001).
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The results of prophylactic treatment of rats with PA against
Fe-NTA-induced elevation in XO level and MDA formation is
shown in Figs 5 and 6. There was enhancement of XO levels
by 50% and MDA levels by 146% in only toxicant group as
compared to saline control. Prophylactic administration of PA
prior to Fe-NTA administration significantly decreased the
MDA by 17% at lower dose and by 33% at higher dose and XO
by 25% at dose I and 26% at dose II. However, PA alone group
produced results near to saline control values.
Renal GSH Content and Antioxidant Enzymes Restored
by Pretreatment
Fe-NTA administration leads to 25% depletion of renal GSH,
its metabolizing enzymes. There was marked suppression by
22% of GR enzyme following Fe-NTA administration shown
in Table 1. Pretreatment with PA (0.5% and 1% per kg body
weight) restored renal GSH content by 23% at dose I and by
30% at dose II and GR by 20% at this low dose and by 25% at
the higher dose. Antioxidant enzymes CAT, GPx and G6PD
were depleted by 46, 23 and 50%, respectively as compared
with the saline-treated control group. These antioxidant
enzymes, namely CAT, GPx and G6PD, were significantly
restored by 19, 7 and 34% at dose I and by 67.9, 25.9 and
69.3% at dose II as shown in Table 2.
Discussion
Oxidative stress and inflammation are closely associated with
tumor promotion (32). Iron deposition within kidney tissue is
often related to generation of reactive oxygen species, leading
to oxidative damage, LPO and concomitant increase in serum
toxicity markers and depletion of renal GSH content (33).
Previously, it has been reported that oxidative stress plays an
important role in the pathogenesis of nephrotoxicity caused by
Fe-NTA (34). Tumor promotion, followed by iron adminis-
tration, possibly due to generation of free radicals in the tissue
(35) FeCl3,  OH formed by a reaction of Fe-NTA with H2O2 in
vivo might be involved in nephrotoxicity and renal carcino-
genesis (36). Therefore, administration with Fe-NTA is a good
model to induce oxidative stress producing  OH to investigate
antioxidant nature of PA. The PA is a naturally occurring anti-
cancer compounds, which is effective against a variety of
rodent organ-specific tumor models (15).
In animal studies, monoterpenes exert an anti-tumor efficacy
and can prevent a wide range of tumors with low toxicity,
namely mild gastrointestinal irritation (37). In vitro,a t
pharmacologically achievable levels, PA inhibited cell hyper-
proliferation and induced apoptosis in mammary and hepatic
tumor cell lines (8,38). It is evident from present results that
PA treatment prior to Fe-NTA administration leads to
restoration of renal GSH and its dependent enzymes, namely
GR, GPx and G6PD. The conjugation of electrophilic Phase I
intermediates with GSH, for instance, frequently results in
Figure 4. Results represent mean ± SE of five animals per group. Results
obtained are significantly different from saline-treated group (**P < 0.001).
Results obtained are significantly different from Fe-NTA-treated group (*P <
0.001).
Significance of pretreatment of PA on the Fe-NTA
mediated increase in Xanthine oxidase activity
Figure 5. Results represent mean ± SE of five animals per group. Results
obtained are significantly different from saline-treated group (**P < 0.001).
Results obtained are significantly different from Fe-NTA-treated group
(*P < 0.001). PA, perillyl alcohol; D1 ¼ 0.5%, D2 ¼ 1%.
Figure 6. Results represent mean ± SE of five animals per group. Results
obtained are significantly different from saline-treated group (**P < 0.001).
Results obtained are significantly different from Fe-NTA-treated group
(*P < 0.001). PA, perillyl alcohol; D1 ¼ 0.5%; D2 ¼ 1%.
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and degradation of electrophilic metabolites is well studied
and documented (33).
PA pretreatment in rats diminishes Fe-NTA-induced malan-
odialdehyde formation; with concomitant depletion in
enhanced XO levels with simultaneous suppression of serum
toxicity markers supports the efficacy of PA in improving
renal armory. The mechanism of action of many chemopre-
ventive agents involves alteration of the metabolic fate of
carcinogens by modulating activities of either, or both, the
Phase I and/or Phase II drug metabolizing enzymes. Induction
of Phase II metabolizing/detoxification enzymes enhances
carcinogen inactivation by facilitating the clearance of
activated metabolites through conjugation with GSH and/or
glucuronides (32,33). Phase II enzymes, namely GR, GPX,
etc., which primarily catalyze conjugation reactions (32,39,40)
were significantly induced in PA pretreated rats, gives ample
evidence of its protective nature. Renal damage and toxicity
has often been associated with boost in serum markers, namely
BUN creatinine. Fe-NTA-treated rats showed elevation in
BUN and serum creatinine. Pretreatment of rats with PA
before Fe-NTA depleted the serum toxicity markers apprecia-
bly. Rats treated with PA had BUN and creatinine significantly
lower than those receiving Fe-NTA. These results suggested
that PA may protect against Fe-NTA-induced renal toxicity
and might serve as a novel agent to limit renal injury.
Induction of ODC activity, and consequently rate of DNA
synthesis, is often recognized as an immediate biomarker of
tumor promotion in chemopreventive studies (32). Prophylac-
tic treatment of PA significantly suppressed enhanced ODC
activity and [
3H]thymidine incorporation in renal DNA. These
data gives some insight that PA is a potent defensive measure
against xenobiotics in which there is involvement of free
radicals in toxicity induction. Present results suggest that
oxidative damage in vivo due to Fe-NTA administration is
checkedtocertain amountbyPApretreatmentinrodentmodel.
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